Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals ...

SPRINGFIELD, Mass. (WWLP) – Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Officials investigate rare ...